Theravance Biopharma, Inc. (TBPH)
Market Cap | 490.27M |
Revenue (ttm) | 63.19M |
Net Income (ttm) | -49.40M |
Shares Out | 49.17M |
EPS (ttm) | -1.01 |
PE Ratio | n/a |
Forward PE | 38.14 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 346,407 |
Open | 9.93 |
Previous Close | 9.92 |
Day's Range | 9.71 - 10.10 |
52-Week Range | 7.44 - 11.71 |
Beta | 0.25 |
Analysts | Buy |
Price Target | 13.75 (+37.91%) |
Earnings Date | Nov 12, 2024 |
About TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collabora... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for TBPH stock is "Buy." The 12-month stock price forecast is $13.75, which is an increase of 37.91% from the latest price.
News
Theravance Biopharma to Participate in an Upcoming Investor Conference
DUBLIN , Nov. 20, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am...
Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Of...
Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus...
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, Novem...
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
DUBLIN , Oct. 18, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the publication of a sub-study of the pivotal 12-week, random...
Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhon...
Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 2023 1 Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023 Partner Viatri...
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
DUBLIN , July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update after market close on Monday, Augus...
Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2024 Earnings Call Transcript May 13, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhonda...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Q1 2024 YUPELRI® (revefenacin) net sales of $55.2 million, recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboration revenue of $14.5 million, increased 39% versus Q1 2023, reflecting ...
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 1...
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
DUBLIN , April 10, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM E...
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Q4 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million 1 Full Year 2023 Viatris Collaboration Revenue increased 18% to $...
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2023 financial results and provide a business update after market close on...
Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal
Theravance Biopharma Inc.'s stock TBPH, -0.60% tumbled 21% early Friday,ter the biotech said a Phase 4 trial of its Yupelri treatment for patients with severe to very severe Chronic Obstructive Pulmon...
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
DUBLIN , Jan. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily...
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and Maximize Shareholder Value DUBLIN , Dec. 21, 2023 /PRNewswire/ --...
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
DUBLIN , Dec. 18, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team including Rick E Winningh...
Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System
DUBLIN , Nov. 16, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of ampreloxetine data in ne...
Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference
DUBLIN , Nov. 15, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference Tuesday, November 28 at 1:45 p...
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Top-line results from Phase III study in China demonstrate the efficacy and safety profile of YUPELRI in patients with COPD PITTSBURGH and DUBLIN , Nov. 13, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: ...
Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Call Transcript
Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Call Transcript
Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
Q3 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q3 2022, reaching an all-time high of $58.3 million 1 Progress made towards the achievement of non-GAAP profitability...
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023
DUBLIN , Oct. 19, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2023 financial results and provide a business update after market close on Tuesday, Novem...